


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
“ELTROMBOPAG OLAMINE TABLETS” APPROVED FOR MARKETING

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the “Eltrombopag Olamine Tablets” (Trade name: Taipusheng (泰普升)) developed by the Group has obtained the approval for marketing from the National Medical Products Administration of China for use in adults and children aged 6 years and above patients with chronic immune (idiopathic) thrombocytopenia (ITP), who have not responded well to previous treatment with glucocorticoids and immunoglobulins, so as to increase platelet count and reduce or prevent bleeding. This product is only used for ITP patients who have an increased risk of bleeding due to thrombocytopenia and clinical conditions.

Eltrombopag Olamine Tablet is an oral, small molecule, non-peptide thrombopoietin receptor agonist (TPO-RA) that acts to increase the number of platelets. In the “Chinese Guidelines for Treatment of Adult Primary Immune Thrombocytopenia (2020 edition)”, eltrombopag is the only drug with the highest level (1a) of evidence and Class A recommendation, and it is also the only thrombopoietic drug approved for the indication of ITP in children over 6 years old in China.

Compared with other ITP drugs, eltrombopag has the following advantages:

1. **High efficacy:** Regardless of whether used for short-term or long-term treatment of ITP, it can significantly increase platelet count and reduce bleeding symptoms. ITP patients who have failed the first-line ITP treatment or have refractory ITP can be treated with eltrombopag, and most of them can have their platelet counts effectively increased and risk of bleeding reduced.
2. **Convenient medication and high compliance:** Simple and convenient oral administration. There is no need to be taken on an empty stomach, which removes the restriction of consuming food before administration and greatly improves medication compliance.

ITP is an acquired, immune, and hemorrhagic disorder, which is an autoimmune disease caused by immune-mediated megakaryocyte injury, resulting in decreased functional platelet production and production of defective platelets. Clinically, ITP is often characterized by thrombocytopenia and systemic skin, mucosa and visceral bleeding. The incidence rate of adults is about 50~10/100,000, and women of childbearing age and the elderly are high-risk groups. The incidence rate in children is about 4~5/100,000, but the incidence of severe bleeding is significantly higher than that of adult patients, which requires long-term standardized management and leads to poorer quality of life, and effective treatment methods are urgently needed. Eltrombopag Olamine Tablet is the world's first oral drug for this indication, with global revenue of more than US\$2 billion in 2022.

Taipusheng has the same dosage form as the brand-name drug, and the bioequivalence of Taipusheng with the reference preparation has been fully confirmed through fasting and postprandial human bioequivalence tests. The approval of Taipusheng will further enrich the treatment options for ITP patients, reduce treatment costs, ease the economic pressure of medication on patients, and contribute to the development of pediatric medication in China. The Group will continue to launch clinically necessary, high-quality and economical drugs to bring good news to the vast population of patients in the future.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 17 January 2024

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.